Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Surgery Partners (SGRY) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Surgery Partners (SGRY) over the last 12 years, with Q3 2025 value amounting to $208.9 million.

  • Surgery Partners' Cost of Revenue rose 372.39% to $208.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $862.7 million, marking a year-over-year increase of 988.41%. This contributed to the annual value of $812.9 million for FY2024, which is 911.41% up from last year.
  • Latest data reveals that Surgery Partners reported Cost of Revenue of $208.9 million as of Q3 2025, which was up 372.39% from $215.0 million recorded in Q2 2025.
  • Surgery Partners' Cost of Revenue's 5-year high stood at $223.0 million during Q4 2024, with a 5-year trough of $147.3 million in Q1 2021.
  • For the 5-year period, Surgery Partners' Cost of Revenue averaged around $186.5 million, with its median value being $188.4 million (2023).
  • As far as peak fluctuations go, Surgery Partners' Cost of Revenue soared by 4305.18% in 2021, and later increased by 21.23% in 2024.
  • Over the past 5 years, Surgery Partners' Cost of Revenue (Quarter) stood at $171.5 million in 2021, then grew by 11.6% to $191.4 million in 2022, then increased by 1.99% to $195.2 million in 2023, then grew by 14.24% to $223.0 million in 2024, then decreased by 6.32% to $208.9 million in 2025.
  • Its last three reported values are $208.9 million in Q3 2025, $215.0 million for Q2 2025, and $215.8 million during Q1 2025.